Associated Papers
Proposed framework for triage of putative germline variants detected via tumour genomic testing in UK oncology practice.
McVeigh TP et al.
Journal of Medical Genetics, 2025
Four decades of the RET gene: From discovery to tumor-agnostic therapy.
Takahashi M
Journal of the Formosan Medical Association = Taiwan Yi Zhi, 2025
Discovery of APS03118, a Potent and Selective Next-Generation RET Inhibitor with a Novel Kinase Hinge Scaffold.
Zhong J et al.
Journal of Medicinal Chemistry, 2025
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present).
Armstrong D et al.
Expert Opinion on Therapeutic Patents, 2025
Prioritization of predisposition genes for familial non-medullary thyroid cancer by whole-genome sequencing.
Srivastava A et al.
European Journal of Endocrinology, 2025
YAP Regulates HER3 Signaling-Driven Adaptive Resistance to RET Inhibitors in RET-Aberrant Cancers.
Katayama Y et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2025
Treatment of non-small cell lung cancer with RET rearrangements.
Hoe HJ et al.
Cancer, 2025
Mechanisms of resistance to RET-directed therapies.
Clifton-Bligh RJ
Endocrine-related Cancer, 2025
Structure-Based Design of 2-Aminopyrazolpyrimidopyridone Derivatives as New Rearranged During Transfection (RET) Kinase Inhibitors.
Shen J et al.
Chemical Biology & Drug Design, 2025
Overview of management and therapeutic advances in medullary thyroid cancer.
Jara MA et al.
Endocrine Oncology (bristol, England), 2025
Hereditary Medullary Thyroid Cancer: Genotype-Phenotype Correlation.
Frank-Raue K et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2025
Systemic Therapies for Advanced Medullary Thyroid Carcinoma.
Santillan MR et al.
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer, 2025
MIG6 loss increased RET inhibitor tolerant persister cells in RET-rearranged non-small cell lung cancer.
Wei X et al.
Cancer Letters, 2024
Primary resistance to selpercatinib in a patient with advanced medullary thyroid cancer.
Pitoia F et al.
Endocrine, 2024
Molecular genetics, therapeutics and RET inhibitor resistance for medullary thyroid carcinoma and future perspectives.
Zhang Y et al.
Cell Communication and Signaling : Ccs, 2024
Germline functional variants contribute to somatic mutation and outcomes in neuroblastoma.
Seo ES et al.
Nature Communications, 2024
Side Chain Investigation of Imidazopyridazine as a Hinge Binder for Targeting Actionable Mutations of RET Kinase.
Maturi A et al.
Acs Medicinal Chemistry Letters, 2024
Thyroid Malignancy and Cutaneous Lichen Amyloidosis: Key Points Amid RET Pathogenic Variants in Medullary Thyroid Cancer/Multiple Endocrine Neoplasia Type 2 (MEN2).
Stanescu LS et al.
International Journal of Molecular Sciences, 2024
Non-Small-Cell Lung Cancers (NSCLCs) Harboring RET Gene Fusion, from Their Discovery to the Advent of New Selective Potent RET Inhibitors: "Shadows and Fogs".
Spitaleri G et al.
Cancers, 2024
Developing Dynamic Structure-Based Pharmacophore and ML-Trained QSAR Models for the Discovery of Novel Resistance-Free RET Tyrosine Kinase Inhibitors Through Extensive MD Trajectories and NRI Analysis.
Sayyah E et al.
Chemmedchem, 2024
RET kinase inhibitors for the treatment of RET-altered thyroid cancers: Current knowledge and future directions.
Hamidi S et al.
Annales D'endocrinologie, 2024
Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations.
Wang ZX et al.
Journal of Medicinal Chemistry, 2024
[Precision medicine in endocrinology exemplified by medullary thyroid cancer].
Brandenburg T et al.
Innere Medizin (heidelberg, Germany), 2024
Characterization of the Thyroid Cancer Genomic Landscape by Plasma-Based Circulating Tumor DNA Next-Generation Sequencing.
Tarasova VD et al.
Thyroid : Official Journal of the American Thyroid Association, 2024
The Evolving Treatment Landscape of Medullary Thyroid Cancer.
Laganà M et al.
Current Treatment Options in Oncology, 2023
Expert consensus on the diagnosis and treatment of RET gene fusion non-small cell lung cancer in China.
Pu X et al.
Thoracic Cancer, 2023
Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET.
Sahakian N et al.
Cancers, 2023
Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations.
Miyazaki I et al.
Nature Cancer, 2023
From Circulating Tumor Cells to Mirna: New Challenges in the Diagnosis and Prognosis of Medullary Thyroid Cancer.
Ricci C et al.
Cancers, 2023
Looking for RET alterations in thyroid cancer: clinical relevance, methodology and timing.
Elisei R et al.
Endocrine, 2023
D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms.
Porcelli T et al.
Jco Precision Oncology, 2023
Progress and challenges in RET-targeted cancer therapy.
Hu X et al.
Frontiers of Medicine, 2023
RET aberrant cancers and RET inhibitor therapies: Current state-of-the-art and future perspectives.
Addeo A et al.
Pharmacology & Therapeutics, 2023
Medullary thyroid cancer - An update.
Fugazzola L
Best Practice & Research. Clinical Endocrinology & Metabolism, 2023
A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion.
Wijewardene A et al.
Thyroid : Official Journal of the American Thyroid Association, 2023
Blood Liquid Biopsy in an Advanced Medullary Thyroid Carcinoma: A Case Study with Rearranged during Transfection Heterogeneity.
Gumà J et al.
Pathobiology : Journal of Immunopathology, Molecular and Cellular Biology, 2023
Multiple endocrine neoplasia type 2 (MEN2) and RET specific modifications of the ACMG/AMP variant classification guidelines and impact on the MEN2 RET database.
Margraf RL et al.
Human Mutation, 2022
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A et al.
Biochimica Et Biophysica Acta. Reviews on Cancer, 2022
RET Proto-Oncogene-Not Such an Obvious Starting Point in Cancer Therapy.
Kucharczyk T et al.
Cancers, 2022
MANAGEMENT OF ENDOCRINE DISEASE: Medullary thyroid cancer: from molecular biology and therapeutic pitfalls to future targeted treatment perspectives.
Saltiki K et al.
European Journal of Endocrinology, 2022
The Role of the Kinase Inhibitors in Thyroid Cancers.
Cuomo F et al.
Pharmaceutics, 2022
Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
Ali F et al.
Archives of Pharmacal Research, 2022
The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
Rosen EY et al.
Nature Communications, 2022
Sporadic Medullary Thyroid Carcinoma: Towards a Precision Medicine.
Matrone A et al.
Frontiers in Endocrinology, 2022
RET kinase inhibitors for RET-altered thyroid cancers.
Vodopivec DM et al.
Therapeutic Advances in Medical Oncology, 2022
GLOBAL ENDOCRINOLOGY: Geographical variation in the profile of RET variants in patients with medullary thyroid cancer: a comprehensive review.
Maciel RMB et al.
European Journal of Endocrinology, 2021
Precision therapy for RET-altered cancers with RET inhibitors.
Thein KZ et al.
Trends in Cancer, 2021